12.50
price down icon0.24%   -0.03
after-market Handel nachbörslich: 12.05 -0.45 -3.60%
loading
Schlusskurs vom Vortag:
$12.53
Offen:
$12.17
24-Stunden-Volumen:
1.64M
Relative Volume:
1.44
Marktkapitalisierung:
$886.80M
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-2.6427
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
+15.31%
1M Leistung:
+5.57%
6M Leistung:
+169.98%
1J Leistung:
-18.19%
1-Tages-Spanne:
Value
$11.48
$12.77
1-Wochen-Bereich:
Value
$10.64
$12.77
52-Wochen-Spanne:
Value
$2.21
$19.50

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name
Firmenname
Phathom Pharmaceuticals Inc
Name
Telefon
(877) 742-8466
Name
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Name
Mitarbeiter
427
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
PHAT's Discussions on Twitter

Vergleichen Sie PHAT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PHAT
Phathom Pharmaceuticals Inc
12.50 838.55M 114.04M -330.15M -274.85M -4.73
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
412.22 104.45B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
469.36 60.95B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.60 59.11B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
812.95 49.23B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ONC
Beone Medicines Ltd Adr
320.94 35.92B 4.56B -176.77M 225.30M -1.7177

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-14 Eingeleitet Cantor Fitzgerald Overweight
2024-05-03 Eingeleitet Stifel Buy
2024-01-05 Bestätigt Needham Buy
2023-08-09 Eingeleitet H.C. Wainwright Buy
2023-05-11 Hochstufung Evercore ISI In-line → Outperform
2023-03-13 Eingeleitet Craig Hallum Buy
2022-10-21 Eingeleitet Jefferies Buy
2022-05-06 Herabstufung Evercore ISI Outperform → In-line
2021-05-12 Hochstufung Goldman Sell → Neutral
2021-02-17 Eingeleitet BMO Capital Markets Outperform
2021-02-02 Eingeleitet Guggenheim Buy
2020-06-26 Herabstufung Goldman Neutral → Sell
2019-11-20 Eingeleitet Evercore ISI Outperform
2019-11-19 Eingeleitet Goldman Neutral
2019-11-19 Eingeleitet Jefferies Buy
2019-11-19 Eingeleitet Needham Buy
Alle ansehen

Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten

pulisher
05:00 AM

How sentiment analysis helps forecast Phathom Pharmaceuticals Inc.Portfolio Value Report & Consistent Income Trade Recommendations - newser.com

05:00 AM
pulisher
Oct 13, 2025

Does Phathom Pharmaceuticals Inc. fit your quant trading modelWeekly Stock Summary & Daily Stock Trend Reports - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Is Phathom Pharmaceuticals Inc. stock a buy on dips2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Will Phathom Pharmaceuticals Inc. stock reach all time highs in 2025Trade Risk Report & Safe Entry Trade Signal Reports - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Is Phathom Pharmaceuticals Inc. stock positioned for digital transformationJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Using economic indicators to assess Phathom Pharmaceuticals Inc. potentialJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Statistical indicators supporting Phathom Pharmaceuticals Inc.’s strength2025 Price Targets & Free Long-Term Investment Growth Plans - newser.com

Oct 12, 2025
pulisher
Oct 10, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 6.8%Still a Buy? - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Will Phathom Pharmaceuticals Inc. continue its uptrendDay Trade & AI Powered Market Trend Analysis - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat

Oct 10, 2025
pulisher
Oct 10, 2025

Is Phathom Pharmaceuticals Inc. meeting your algorithmic filter criteriaJuly 2025 Short Interest & Long-Term Growth Plans - newser.com

Oct 10, 2025
pulisher
Oct 09, 2025

Cantor Fitzgerald reiterates Phathom stock as top pick with $29 price target - Investing.com Canada

Oct 09, 2025
pulisher
Oct 09, 2025

Leading vs lagging indicators on Phathom Pharmaceuticals Inc. performanceMarket Performance Report & Long-Term Capital Growth Strategies - newser.com

Oct 09, 2025
pulisher
Oct 09, 2025

Why hedge funds are buying Phathom Pharmaceuticals Inc. stockJuly 2025 Decliners & Fast Exit Strategy with Risk Control - newser.com

Oct 09, 2025
pulisher
Oct 08, 2025

Phathom Pharmaceuticals Hits Day Low of $10.33 Amid Price Pressure - Markets Mojo

Oct 08, 2025
pulisher
Oct 08, 2025

When Will Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Breakeven? - simplywall.st

Oct 08, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer By Investing.com - Investing.com Nigeria

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 7.8%Here's What Happened - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer - citybiz

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals, Inc. Appoints Sanjeev Narula as Chief Financial and Business Officer - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

When is the best time to exit Phathom Pharmaceuticals Inc.Global Markets & Expert Approved Trade Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial officer - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals Appoints New Chief Financial Officer - TipRanks

Oct 06, 2025
pulisher
Oct 06, 2025

Phathom Pharmaceuticals appoints Sanjeev Narula as chief financial and business officer - Investing.com

Oct 06, 2025
pulisher
Oct 06, 2025

Using Bollinger Bands to evaluate Phathom Pharmaceuticals Inc.2025 Technical Overview & Stock Portfolio Risk Management - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Analyzing recovery setups for Phathom Pharmaceuticals Inc. investorsSwing Trade & Long-Term Safe Investment Ideas - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Will Phathom Pharmaceuticals Inc. see short term momentumQuarterly Growth Report & Low Drawdown Trading Strategies - newser.com

Oct 06, 2025
pulisher
Oct 05, 2025

Tools to monitor Phathom Pharmaceuticals Inc. recovery probabilityJuly 2025 Summary & Safe Capital Preservation Plans - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How to integrate Phathom Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com

Oct 05, 2025
pulisher
Oct 05, 2025

How Phathom Pharmaceuticals Inc. stock reacts to Fed rate cutsQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com

Oct 05, 2025
pulisher
Oct 03, 2025

What Fibonacci levels say about Phathom Pharmaceuticals Inc. reboundMarket Risk Report & Daily Stock Momentum Reports - newser.com

Oct 03, 2025
pulisher
Oct 03, 2025

How to build a custom watchlist for Phathom Pharmaceuticals Inc.July 2025 Decliners & Expert Verified Stock Movement Alerts - newser.com

Oct 03, 2025
pulisher
Oct 02, 2025

Published on: 2025-10-02 20:30:06 - newser.com

Oct 02, 2025
pulisher
Oct 01, 2025

Phathom Pharmaceuticals Experiences Evaluation Revision Amid Mixed Performance Indicators - Markets Mojo

Oct 01, 2025
pulisher
Oct 01, 2025

Published on: 2025-10-01 09:34:59 - newser.com

Oct 01, 2025

Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Breedlove Robert Charles
Principal Accounting Officer
Sep 05 '25
Sale
12.09
461
5,573
47,931
Breedlove Robert Charles
Principal Accounting Officer
Jul 16 '25
Sale
8.36
1,692
14,152
48,392
Topper James N
Director
May 21 '25
Buy
3.86
3,780
14,609
59,403
Topper James N
Director
May 14 '25
Buy
3.32
6,300
20,919
55,623
Topper James N
Director
May 13 '25
Buy
3.16
1,120
3,543
49,323
Topper James N
Director
May 09 '25
Buy
3.22
35,602
114,616
35,602
Topper James N
Director
May 12 '25
Buy
3.04
12,601
38,301
48,203
Parikh Asit
Director
May 06 '25
Buy
2.60
5,000
13,000
90,500
Parikh Asit
Director
May 07 '25
Buy
2.40
5,000
11,984
95,500
Henderson Molly
CFO and CBO
Apr 07 '25
Sale
4.55
3,678
16,740
89,868
$21.75
price down icon 5.15%
$85.96
price up icon 1.45%
$32.75
price up icon 0.21%
$102.61
price up icon 0.30%
$161.38
price down icon 1.56%
biotechnology ONC
$320.94
price down icon 1.86%
Kapitalisierung:     |  Volumen (24h):